SCHEMBL6325226

SCHEMBL6325226

CN(CCO)C(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.44
OPRM1 P35372 4/20 0.43
OPRL1 P41146 1/20 0.43
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 4/20 0.41
CHRM2 P08172 1/20 0.41
CHRM4 P08173 1/20 0.41
CHRM5 P08912 1/20 0.41
CHRM1 P11229 1/20 0.41
CHRM3 P20309 1/20 0.41
DRD3 P35462 3/20 0.40
DRD2 P14416 2/20 0.40
DRD4 P21917 2/20 0.40
CYP2D6 P10635 3/20 0.39
CYP2C19 P33261 2/20 0.39
HSD17B10 Q99714 1/20 0.39
LMNA P02545 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20710184 0.91 KCNN4 (0.44) KCNN4SMN1; SMN2OPRM1OPRL1MEN1
SCHEMBL14612482 0.87 KIF11 (0.45) KCNN4KDM4EALDH1A1TSHR
SCHEMBL31284873 0.80 SMN1; SMN2 (0.46) KCNN4SMN1; SMN2OPRM1OPRL1MEN1
SCHEMBL10408983 0.79 KCNN4 (0.52) KCNN4SMN1; SMN2OPRM1MEN1KMT2A
SCHEMBL9740041 0.79 KCNN4 (0.52) KCNN4SMN1; SMN2OPRM1MEN1KMT2A
SCHEMBL9556171 0.79 KCNN4 (0.52) KCNN4SMN1; SMN2OPRM1MEN1KMT2A
SCHEMBL3747207 0.79 KCNN4 (0.52) KCNN4SMN1; SMN2OPRM1CHRM2CHRM4
SCHEMBL2490290 0.78 ALDH1A1 (0.46) KCNN4SMN1; SMN2OPRM1OPRL1MEN1
SCHEMBL7396322 0.78 MEN1 (0.45) KCNN4SMN1; SMN2OPRM1OPRL1MEN1
SCHEMBL3503920 0.77 KCNN4 (0.45) KCNN4SMN1; SMN2MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017141035-A1 METHOD CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 2017-08-24 WO disclosed
US-20050049245-A1 Heteroaryl-ethanolamine derivatives as antiviral agents PHARMACIA & UPJOHN COMPANY 2005-03-03 US disclosed
US-6852731-B2 Antiviral compounds PFIZER (US) 2005-02-08 US disclosed
WO-2004106345-A2 HETEROARYL-ETHANOLAMINE DERIVATIVES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2004-12-09 WO disclosed
US-20040242884-A1 ANTIVIRAL COMPOUNDS PHARMACIA & UPJOHN COMPANY 2004-12-02 US disclosed
EP-1472260-A2 THIENO(3,2-B)PYRIDONES AS ANTIVIRAL COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2004-11-03 EP disclosed
WO-2003059878-A2 THIENO (3, 2-B) PYRIDONES AS ANTIVIRAL COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242884-A1 ANTIVIRAL COMPOUNDS ZC3HAV1, IRF3, IFNAR1 KCNN4 2186/4885SMN1; SMN2 947/4885OPRM1 2311/4885
US-20050049245-A1 Heteroaryl-ethanolamine derivatives as antiviral agents RPL35, ZC3HAV1, RPL5 KCNN4 4581/4885SMN1; SMN2 4631/4885OPRM1 882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.